Suppressive therapy manages clopidogrel hypersensitivityApril 8th 2011
Clopidogrel hypersensitivity, which affects 6% of patients, can be successfully treated using short-course corticosteroids and antihistamines without interrupting drug therapy, reported researchers at Jefferson Medical College in Philadelphia.
Combination of ACEI and ARB therapy increases renal risks in elderlyApril 8th 2011
Combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers is associated with increased risk of adverse renal outcomes, according to a recent study published in the Canadian Medical Association Journal.
High-dose clopidogrel does not reduce mortality after PCIApril 1st 2011
The use of high-dose clopidogrel compared with use of standard-dose clopidogrel does not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis among patients with high on-treatment reactivity after percutaneous coronary intervention with drug-eluting stents, according to a recent multicenter study published in the Journal of the American Medical Association.
FDA continues its review of abacavir: Evidence does not suggest an increased risk of myocardial infarctionApril 1st 2011
Available evidence reviewed by FDA does not suggest abacavir is associated with an increased risk of myocardial infarction, according to an updated safety communication released March 2011.
Ambulatory blood pressure lowering efficacy of hydrochlorothiazide inferior to other drug classesApril 1st 2011
Investigators question whether the thiazide diuretic, hydrochlorothiazide, should be used as commonly as it is for treating hypertension, according to a report published in a recent edition of the Journal of the American College of Cardiology.
Cost of heart failure drugs impacts medication adherenceApril 1st 2011
In a new study published ahead of print on the Mayo Clinic Proceedings website, researchers demonstrated that the cost of medications was a factor influencing the proportion of patients with heart failure who had poor medication adherence to beta-blockers, angiotensin converting-enzyme inhibitors or receptor blockers, and statins.
New guidelines for atrial fibrillation management incorporate dabigatranApril 1st 2011
An update on the management of atrial fibrillation issued by a task force consisting of the American College of Cardiology Foundation, the American Heart Association, and the Heart Rhythm Society has incorporated dabigatran into its recommendations.
Both benefits and adverse effects influence elderly's adherence to cardiovascular medicationMarch 18th 2011
The willingness of the elderly to take medication for primary cardiovascular disease prevention is relatively insensitive to its benefit but highly sensitive to its adverse effects, according to a recent study published in the Archives of Internal Medicine.
FDA: Monthly liver enzyme tests no longer needed for PAH drugMarch 11th 2011
FDA has approved a change to the prescribing information for ambrisentan 5-mg and 10-mg tablets (Letairis, Gilead Sciences) once-daily treatment to improve exercise ability and delay clinical worsening in patients with pulmonary arterial hypertension (PAH, WHO Group 1) and predominantly WHO Functional Class II-III symptoms.
Rosiglitazone label and medication guide updated with cardiovascular risksFebruary 18th 2011
FDA has announced that the physician labeling and patient medication guide for rosiglitazone (Avandia, GlaxoSmithKline) have been changed to include information on cardiovascular risks (including death) of this agent.
Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillationFebruary 1st 2011
The recently FDA-approved oral direct thrombin inhibitor, dabigatran, may be cost-effective compared to the standard-of-care therapy of adjusted-dose warfarin in patients requiring anticoagulation for stroke prevention in atrial fibrillation, according to a pharmacoeconomic evaluation published in the Annals of Internal Medicine.
Physicians welcome dabigatran etexilate as alternative to warfarinJanuary 7th 2011
In a guest editorial, 2 researchers highlighted the importance of the FDA approval in October of dabigatran etexilate (Pradaxa, Boehringer Ingelheim), an oral thrombin inhibitor that provides an alternative to warfarin (Coumadin, Bristol-Myers Squibb) for long-term stroke prevention in patients with non-valvular atrial fibrillation.
New 3-drug regimen improves outcomes for myeloma patientsJanuary 7th 2011
The addition of bortezomib to the standard induction therapy before double autologous stem cell transplantation for patients with multiple myeloma appears to improve nearly threefold the rates of complete or near complete response, according to research published online in The Lancet, HealthDay News reported.
Combining statins and fibrates increases rhabdomyolysis riskJanuary 7th 2011
Patients who are newly treated with statin-fibrate concurrent therapy are slightly more likely to be hospitalized with rhabdomyolysis than those who take just one of the medications, according to research published in the American Journal of Cardiology, HealthDay News reported.
Angiotensin receptor blockers may not reduce mortality in diabetes, hypertension settingsJanuary 1st 2011
Antihypertensive therapy with an angiotensin receptor blocker is not associated with reductions in cardiovascular or all-cause mortality compared to non-ARB-based regimens in patients with type 2 diabetes, according to researchers at the Massachusetts College of Pharmacy and Health Sciences.
Protease inhibitor saquinavir linked to QT, PR interval prolongationJanuary 1st 2011
FDA is requiring a new warning be added to the prescribing information for saquinavir (Invirase) detailing the drug's potential to prolong both QT and PR intervals on an electrocardiogram, and thus potentially cause the dangerous abnormal heart rhythms called torsades de pointes and complete heart block.
Pfizer voluntarily withdraws sitaxsentan from the market worldwide and halts ongoing clinical trialsJanuary 1st 2011
Based on "a review of emerging safety information from clinical trials and postmarketing reports," Pfizer announced it would be voluntarily withdrawing sitaxsentan (Thelin), the manufacturer's pulmonary artery hypertension (PAH) treatment from the market worldwide.
FDA alerts to ongoing olmesartan cardiovascular reviewJuly 1st 2010
On June 11, 2010, FDA announced in a drug safety communication that the agency was currently evaluating whether the use of the angiotensin II receptor blocker olmesartan (Benicar, Daiichi Sankyo) (also sold in combination with hydrocholorothiazide as Benicar HCT) was associated with increased cardiovascular mortality.
Perioperative fluvastatin treatment associated with improved CV outcome after noncardiac vascular surgerySeptember 14th 2009
In the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography III (DECREASE III) trial published in the New England Journal of Medicine, patients undergoing noncardiac vascular surgery who were treated with perioperative fluvastatin demonstrated a lower incidence of myocardial ischemia than patients treated with placebo.
Ticagrelor associated with lower rate of death from vascular causes, MI, and strokeSeptember 14th 2009
In the Study of Platelet Inhibition and Patient Outcomes (PLATO) published in the New England Journal of Medicine, patients with acute coronary syndrome (ACS) who were treated with ticagrelor had significant reductions in the rate of death from vascular causes, myocardial infarction (MI), or stroke and no significant increase in the rate of overall major bleeding versus patients treated with clopidogrel.
P&T considerations in fashioning a knowledge base, action plan for cardiometabolic disorders and weightSeptember 1st 2009
The P&T committee is positioned to provide knowledge, strategies to improve treatment of patients with cardiometabolic disorders.
Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III
This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.
Dronedarone (Multaq): Benzofuran derivative approved to reduce the risk of CV hospitalization in patients with AFAugust 1st 2009
New molecular entity: Dronedarone (Multaq), a benzofuran derivative, was approved on July 1, 2009, to reduce the risk of CV hospitalization in patients with AF
Prasugrel (Effient): Platelet activation and aggregation inhibitor approved to reduce the rate of thrombotic CV events in patients with ACS undergoing PCIAugust 1st 2009
New molecular entity: Prasugrel (Effient), a platelet activation and aggregation inhibitor, was approved on July 10, 2009, to reduce the rate of thrombotic CV events in patients with ACS undergoing PCI